Skip to main content

and
  1. Article

    Open Access

    Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

    Health-related quality of life (HRQoL) may be markedly impaired in patients with moderate-to-severe psoriasis.

    April W. Armstrong, Kristian Reich, Peter Foley in American Journal of Clinical Dermatology (2019)

  2. No Access

    Article

    Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

    Guselkumab effectively treats moderate-to-severe psoriasis.

    Kristian Reich, April W. Armstrong, Peter Foley in American Journal of Clinical Dermatology (2020)

  3. Article

    Open Access

    Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis

    The aim of this study was to evaluate guselkumab efficacy on regional psoriasis in a subset of psoriasis patients with a self-reported psoriatic arthritis (PsA) diagnosis.

    Ana-Maria Orbai, Soumya D. Chakravarty, Yin You, May Shawi in Dermatology and Therapy (2023)